about
Managing comorbidities in COPDAmbroxol in the 21st century: pharmacological and clinical updateDirect costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data."Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.Pneumocafé project: an inquiry on current COPD diagnosis and management among General Practitioners in Italy through a novel tool for professional education.Economic evaluation of a disease management program for chronic obstructive pulmonary disease.Study of drug utilization pattern for acute exacerbation of chronic obstructive pulmonary disease in patients attending a government hospital in kerala, IndiaThe economic impact of chronic obstructive pulmonary disease.Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD)Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE studyPatterns and determinants of COPD-related healthcare utilization by severity of airway obstruction in KoreaNutritional status of chronic obstructive pulmonary disease patients admitted in hospital with acute exacerbation.Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease.Formoterol: a review of its use in chronic obstructive pulmonary disease.Municipality screening of citizens with suspicion of chronic obstructive pulmonary diseaseCost-effectiveness analysis of three different combinations of inhalers for severe and very severe chronic obstructive pulmonary disease patients at a tertiary care teaching hospital of South India.Maintenance pharmacotherapy of chronic obstructive pulmonary disease: an evidence-based approach.Statement on home care for patients with respiratory disorders.COPD a social disease: inappropriateness and pharmaco-economics. The role of the specialist: present and future.Geographic variation in chronic obstructive pulmonary disease exacerbation ratesPatient's perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study.Outcome measures for COPD treatments: a critical evaluation.Factors associated with outcomes of acute exacerbations of chronic obstructive pulmonary disease.Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature.Dysregulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis.Optimizing economic outcomes in the management of COPD.Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare costRole of tiotropium in the treatment of COPD.An international randomized study of a home-based self-management program for severe COPD: the COMETAcute exacerbation of COPD: is it the "stroke of the lungs"?Determinants and predictors of the cost of COPD in primary care: a Spanish perspective.Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish Study.Impact of lung function on exacerbations, health care utilization, and costs among patients with COPDBacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections.Polymorphic variation in surfactant protein B is associated with COPD exacerbations.Cost Analysis of Hospitalized Patients with Chronic Obstructive Pulmonary Disease: A State-Level Cross-Sectional Study.Description of the disease and diagnostic and epidemiologic aspects.Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
P2860
Q27005858-9760BB7B-758C-4B6D-8B76-EC06135E7D0CQ28289778-2EB44F83-150F-4B1C-BEE6-C10CBA957271Q31082713-86A04349-8277-42D1-8AE9-9C5C3D5DD876Q33693227-832D1972-F77C-4256-8FD9-AE1E1E7E663AQ33770577-B65366B1-082D-44A3-BEA2-5ABFF2D7636DQ34179982-4FB6E499-DC8B-4D23-BFE6-B817819E129AQ34405926-0695A117-7B9B-46BC-BFB1-D2144B9FEE86Q34544695-A6433C4E-7A50-4A68-AE51-A75EA88D55F6Q34612842-24FA7726-4C78-4FFC-AA9D-A56702013DF1Q34944637-7FCE511F-7FC4-437E-AD4A-5448BAE0785CQ35103337-87FBE668-661F-44FC-9004-131D4047A165Q35119842-50B9F1BF-B1DE-40D0-83A8-4BA286B7C9A1Q35537270-7AE43511-E3FC-45DF-A697-48650543E617Q35537594-445B6CB2-B55E-48E8-AC00-331558164850Q35627804-990E823D-87FF-4723-B5E1-3AE4AB593549Q35627824-3065B719-EC52-48B7-BFC3-AD30EAA71C1BQ35739573-AA4C06AE-6997-4640-9894-9FC4121C4191Q35856708-AF4C42EF-5E76-470F-9F84-908D931CF1CEQ36040655-E5C51EB0-CEAA-4843-B26B-CFE1CB35E7F5Q36154887-EE33F6DE-4294-40A1-92B3-F0635F5767ABQ36293842-ED2A3F32-A1B3-4A9D-BF8E-545F1A0E15CFQ36416859-93CA3864-8992-4F37-A273-62BF255B395AQ36485759-BF53782A-E484-48AE-A543-738C69B6CF69Q36602287-9FA52270-2317-47F3-915B-78C97F6E3D18Q36669477-0DFA73A5-E04B-4BC9-B23F-B5EDF7DDDF72Q36760100-BD93C4FC-40D5-4C66-A925-9BA53869FCBBQ36778601-B3434CE1-A728-4111-B0A1-49CF6872A060Q36859405-8F906ABB-98FE-49F2-86FF-3D32C4EEB469Q36980698-4990F186-22B2-4FAF-BD95-58CDC616386DQ37017516-FB717E4B-91F7-4DAA-812A-D3C59155049AQ37069379-813D4F48-2767-49BF-8F84-E00CA0108DC9Q37103385-6C4050B1-0BE1-4999-8D42-69837EBBBD32Q37115948-9C953BD2-F19A-4752-80F9-5B45520C835DQ37115952-50784E54-DA9B-4500-BB60-EE9A21B55EFAQ37142609-7562E352-B823-4727-9A37-1190F8E6D5FDQ37224498-EBA064CA-AB09-4F42-97BD-F80A8628A32CQ37387050-9F807496-43AA-46FE-AF6A-62A833E85C8BQ37451998-9DCF5384-86F8-4AD1-B8E6-CA87BF38E17FQ37811604-361A21D8-1E87-4B8F-A83B-5AA8F2EFDCDFQ38063794-C395F138-C459-448C-943E-8BC781C2802F
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Pharmacoeconomic evaluation of COPD.
@ast
Pharmacoeconomic evaluation of COPD.
@en
Pharmacoeconomic evaluation of COPD.
@nl
type
label
Pharmacoeconomic evaluation of COPD.
@ast
Pharmacoeconomic evaluation of COPD.
@en
Pharmacoeconomic evaluation of COPD.
@nl
prefLabel
Pharmacoeconomic evaluation of COPD.
@ast
Pharmacoeconomic evaluation of COPD.
@en
Pharmacoeconomic evaluation of COPD.
@nl
P2093
P356
P1433
P1476
Pharmacoeconomic evaluation of COPD.
@en
P2093
P304
P356
10.1378/CHEST.118.5.1278
P407
P577
2000-11-01T00:00:00Z